ADC Therapeutics SA has released a corporate presentation highlighting its advancements and strategic direction in the field of antibody-drug conjugates (ADCs). The company emphasizes its specialized end-to-end capabilities from discovery to commercialization, aiming to enhance the therapeutic index of next-generation ADCs through an array of payloads, linkers, and conjugation chemistry. A key focus is on the expansion of the FDA-approved ZYNLONTA® for diffuse large B-cell lymphoma (DLBCL), including potential new indications and combination therapies. Additionally, ADC Therapeutics is pursuing early-stage development in solid tumors, targeting Claudin-6, PSMA, NaPi2b, and ASCT2. The company is also seeking research collaborations to broaden its portfolio. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.